Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform (NASDAQ:ALNY)

seekingalpha.com · 2026-09-28

Alnylam Pharmaceuticals, Inc. is down on ATTR-CM fears. TRITON-CM could still succeed, downside is buffered, and shares look undervalued. Click for an ALNY update.

Read the full story at seekingalpha.com →